---
title: "Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Pathophysiology"
description: "Formulary evidence on Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Pathophysiology. Topics: Mutant huntingtin: toxic gain of function, Striatal degeneration: neuropathological grading, Genetic modifiers of onset: DNA repair genes identified by GWAS, Genetic modifiers of progression: MSH3 and PMS1, and 3 further topics. 7 evidence topics quoted from 11 sources."
canonical: "https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description/pathophysiology"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Pathophysiology

<a id="heading-2.2.1.4"></a>

## 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

### Mutant huntingtin: toxic gain of function

> “In mutation carriers, huntingtin is produced with abnormally long polyglutamine sequences that confer toxic gains of function and predispose the protein to fragmentation, resulting in neuronal dysfunction and death.”

Source: [Bates et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/27188817/)

> “The expanded polyQ tract confers a toxic gain of function, resulting in the dysregulation of vital cellular processes, which ultimately leads to protein aggregation and cell death”

Source: [Caldeira Brás et al. (2026)](https://www.ncbi.nlm.nih.gov/books/NBK1305/)

> “At the cellular level mutant huntingtin results in neuronal dysfunction and death through a number of mechanisms, including disruption of proteostasis, transcription and mitochondrial function and direct toxicity of the mutant protein. Early macroscopic changes are seen in the striatum with involvement of the cortex as the disease progresses.”

Source: [McColgan and Tabrizi (2018)](https://pubmed.ncbi.nlm.nih.gov/28817209/)

<a id="topic-2.2.1.4-2"></a>

### Striatal degeneration: neuropathological grading

> “The earliest changes were seen in the medial paraventricular portions of the caudate nucleus (CN), in the tail of the CN, and in the dorsal part of the putamen. Counts of neurons in the CN reveal that 50% are lost in grade 1 and that 95% are lost in grade 4”

Source: [Vonsattel et al. (1985)](https://pubmed.ncbi.nlm.nih.gov/2932539/)

<a id="topic-2.2.1.4-3"></a>

### Genetic modifiers of onset: DNA repair genes identified by GWAS

> “Association at MLH1 and pathway analysis of the full GWA results support a role for DNA handling and repair mechanisms in altering the course of HD.”

Source: [Genetic Modifiers of Huntington's Disease (GeM-HD) Consortium (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4524551/)

> “The timing of onset shows no significant association with HTT cis-eQTLs but is influenced, sometimes in a sex-specific manner, by polymorphic variation at multiple DNA maintenance genes, suggesting that the special onset-determining property of the uninterrupted CAG repeat is a propensity for length instability that leads to its somatic expansion.”
> “Four genes at 3 loci were significant after Bonferroni correction: FAN1 (p = 1.9E-22), MSH3 (1.9E-8), PMS1 (6.1E-7), and ASNSD1 (5.3E-6) with later onset associated with increased FAN1, PMS1, and ASNSD1 expression and decreased MSH3 expression.”

Source: [Genetic Modifiers of Huntington's Disease (GeM-HD) Consortium (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6700281/)

> “Repeatedly implicated MMR genes include MSH3, MLH1, PMS1, PMS2, and LIG1”

Source: [Caldeira Brás et al. (2026)](https://www.ncbi.nlm.nih.gov/books/NBK1305/)

<a id="topic-2.2.1.4-4"></a>

### Genetic modifiers of progression: MSH3 and PMS1

> “The lead single nucleotide polymorphism (SNP) in TRACK-HD (rs557874766) was genome-wide significant in the meta-analysis”
> “encodes an aminoacid change (Pro67Ala) in MSH3”
> “Knockout of Msh3 reduces somatic expansion in Huntington's disease mouse models, suggesting this mechanism as an area for future therapeutic investigation.”

Source: [Hensman Moss et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28642124/)

> “Genome-wide association studies (GWASs) of Huntington disease (HD) have identified six DNA maintenance gene loci (among others) as modifiers and implicated a two step-mechanism of pathogenesis: somatic instability of the causative HTT CAG repeat with subsequent triggering of neuronal damage.”
> “In addition, we identified additional modifier effects at the PMS1 and PMS2 loci and implicated a potential second locus on chromosome 7.”

Source: [Lee et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9118113/)

<a id="topic-2.2.1.4-5"></a>

### Somatic CAG repeat expansion in striatal projection neurons

> “We found that the HTT CAG repeat expands somatically from 40-45 to 100-500+ CAGs in SPNs. Somatic expansion from 40 to 150 CAGs had no apparent cell-autonomous effect, but SPNs with 150-500+ CAGs lost positive and then negative features of neuronal identity, de-repressed senescence/apoptosis genes, and were lost.”
> “We conclude that in HD, at any one time, most neurons have an innocuous but unstable HTT gene, and that HD pathogenesis is a DNA process for almost all of a neuron’s life.”

Source: [Handsaker et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11822645/)

> “Somatic expansion within the striatum correlates strongly with earlier disease onset”
> “In this model, somatic instability acts as a catalyst for expansion, while a subsequent toxic gain-of-function mechanism drives cell death once the repeat length crosses a critical threshold.”

Source: [Caldeira Brás et al. (2026)](https://www.ncbi.nlm.nih.gov/books/NBK1305/)

<a id="topic-2.2.1.4-6"></a>

### PMS1 as a modifier of somatic CAG repeat expansion

> “Homozygous but not heterozygous inactivation of PMS1 also reduces CAG repeat expansion, supporting PMS1 as a genetic modifier of HD and a potential target for therapeutic intervention.”

Source: [McLean et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11015039/)

<a id="topic-2.2.1.4-7"></a>

### Multiple pathogenic mechanisms

> “Mutant HTT (mHTT) disrupts transcription, interferes with immune and mitochondrial function, and is aberrantly modified post-translationally. Evidence suggests that the mHTT RNA is toxic, and at the DNA level, somatic CAG repeat expansion in vulnerable cells influences the disease course.”

Source: [Tabrizi et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32796930/)

## Related pages
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Terms and abbreviations](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations.md)
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Product information and disease description](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Clinical evidence](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Economic information and modeling report](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: References](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references.md)
